DOSAGE / RESEARCH CONTEXT
The CJC-1295 doses that appear in the published studies
What was administered, to which species, by which route — and why the multi-day half-life makes CJC-1295's schedule unlike a short-acting peptide. No human protocol here.
Doses Used in the Research Literature
CJC-1295 dosage in the published record is narrow and human-PK-focused. The pharmacokinetic studies in healthy adults used single subcutaneous doses of 30, 60, or 90 micrograms/kg [3][1]. The GHRH-knockout mouse growth study used a fixed 2 micrograms per dose at 24-, 48-, or 72-hour intervals, and found that the 24-hour schedule normalized growth while longer intervals were progressively inferior [4]. That is essentially the controlled dosing evidence base.
Beyond it, community and clinic 'protocols' for the no-DAC Modified GRF 1-29 form and for CJC-1295/ipamorelin commonly cite 100-300 microgram fixed doses, but these are not derived from controlled human trials. This digest reports the research doses as research doses; it does not convert them into a human regimen and makes no recommendation.
Half-life and why the schedule is different
Dose interval follows half-life, and CJC-1295's half-life is unusually long for a peptide. The DAC variant's estimated half-life is 5.8-8.1 days in healthy adults, with IGF-1 elevation lasting up to 28 days after multiple doses [3]. The albumin conjugation is the reason: the effective circulating species is the ~66 kDa peptide-albumin complex, not the free peptide.
The no-DAC Modified GRF 1-29 form is short-acting — minutes to hours — because it lacks the albumin handle. A schedule built around one variant is wrong for the other. The mouse work makes the duration concrete: once-daily CJC-1295 was sufficient to normalize growth in GHRH-knockout animals, where every-other-day or every-third-day dosing was not [4].
What the dose numbers describe — and what they don't
The 30, 60, and 90 microgram/kg figures are weight-scaled experimental doses from pharmacokinetic studies, not fixed-amount human regimens [3][1]. They were chosen to characterize the GH and IGF-1 response curve, with biomarker readouts as the endpoint — not to optimize an outcome in a person. The mouse study's 2-microgram fixed dose [4] is a different species, a different scale, and a different question (restoring growth in a knockout), and it does not translate to a human amount either.
That gap is the point. There is no established clinical dose of CJC-1295 for healthy adults, because there is no clinical use of CJC-1295 in healthy adults to dose for. The community 100-300 microgram figures fill that vacuum without controlled-trial support. This page reports the studied numbers so a reader can see exactly how thin and how purpose-specific the dosing evidence is.
How much CJC-1295 should I take?
Published human PK studies used single subcutaneous doses of 30, 60, or 90 micrograms/kg [3][1]; circulating community 'protocols' are not derived from controlled human trials. This digest reports research doses only and makes no human-use recommendation. CJC-1295 is an unapproved research chemical with no established clinical dose for healthy adults.
How to reconstitute CJC-1295?
In research handling the lyophilized peptide is reconstituted with bacteriostatic water and refrigerated. The four substitutions confer DPP-IV and protease resistance, and DAC conjugation confers the multi-day duration; oral bioavailability is negligible because the molecule is a peptide. This is handling context drawn from the research literature, not a use protocol.
Where to inject CJC-1295?
In published research the route studied is subcutaneous injection — the primary route across the human pharmacokinetic studies [3][1]. Intravenous administration appears in the earlier GRF(1-29) pharmacokinetic work [7]. This digest reports the studied routes only; it is not a self-administration guide.